Print

Purpose

This study is being done to learn more about an investigational medicine called PF-08653944. The goal is to understand how the body handles the medicine and to check its safety after a single dose. The study includes adults with normal liver function and adults who have mild, moderate, or severe liver problems. By comparing these groups, researchers want to understand whether liver function changes how the medicine behaves in the body. People who join the study will receive one injection of the study medicine. They will stay at the study clinic for a short time and return for follow-up visits so doctors can do blood tests, physical exams, and safety checks. This study is not expected to provide direct medical benefit to participants. The information collected will help researchers develop future treatments and understand how this medicine may be used safely in people with liver disease.

Condition

Eligibility

Eligible Ages
Between 18 Years and 74 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Adults 18 to 75 years of age, male or female. - BMI ≥21 kg/m² and body weight >50 kg at screening. - Group 1 (without hepatic impairment): - No known or suspected hepatic impairment. - Normal liver function tests (ALT, AST, bilirubin, albumin, PT within normal limits, with protocol-specified exceptions such as Gilbert's syndrome). - Groups 2-4 (with hepatic impairment): - Stable hepatic impairment classified as Child-Pugh Class A (mild), B (moderate), or C (severe). - No clinically significant worsening of hepatic status within 28 days prior to screening. - Women of childbearing potential must not be pregnant or breastfeeding and must agree to use highly effective contraception.

Exclusion Criteria

  • Clinically significant medical or psychiatric conditions, including recent or active suicidal ideation or behavior. - Use of GLP-1 receptor agonists within 90 days (or 5 half-lives) prior to dosing. - Participation in another investigational study or receipt of an investigational product within 30 days (or 5 half-lives) prior to dosing. - For hepatic-impairment groups only: - Hepatic carcinoma, hepatorenal syndrome, or limited life expectancy. - Clinically active Grade 3 or 4 hepatic encephalopathy. - Severe uncontrolled ascites, recent gastrointestinal bleeding, or history of solid organ transplant.

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
N/A
Intervention Model
Parallel Assignment
Primary Purpose
Basic Science
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Group 1 		Participants without Hepatic Impairment (HI) will receive a single dose of PF-08653944, administered as Subcutaneous (SC) injection.
  • Drug: PF-08653944
    Solution for injection
    Other names:
    • MET097
Experimental
Group 2 		Participants with mild HI will receive a single dose of PF-08653944, administered as SC injection.
  • Drug: PF-08653944
    Solution for injection
    Other names:
    • MET097
Experimental
Group 3 		Participants with moderate HI will receive a single dose of PF-08653944, administered as SC injection.
  • Drug: PF-08653944
    Solution for injection
    Other names:
    • MET097
Experimental
Group 4 		Participants with severe HI will receive a single dose of PF 08653944, administered as SC injection.
  • Drug: PF-08653944
    Solution for injection
    Other names:
    • MET097

Recruiting Locations

Floridian Clinical Research
Miami Lakes, Florida 33016

Orlando Clinical Research Center
Orlando, Florida 32809

Genesis Clinical Research
Tampa, Florida 33603

More Details

Status
Recruiting
Sponsor
Pfizer

Study Contact

Pfizer CT.gov Call Center
1-800-718-1021
ClinicalTrials.gov_Inquiries@pfizer.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.